REG - Futura Medical PLC - Block Listing Six Monthly Return

Futura MedicalAnnouncement

31/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220531:nRSe1345Na&default-theme=true

RNS Number : 1345N  Futura Medical PLC  31 May 2022

Block Listing Six Monthly Return

31 May 2022

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products for sexual health and pain relief, makes the following
update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the
AIM Rules for Companies. All figures relate to options over Ordinary Shares of
0.2 pence each (Ordinary Shares).

Date: 31 May 2022

 Name of applicant:                                                                Futura Medical Plc
 Name of scheme:                                                                   Unapproved Share Option Scheme

                                                                                   Unapproved Share Incentive Scheme

                                                                                   EMI Share Option Scheme
 Period of return:                        From:                                    1 December 2021     To:                 31 May 2022
 Balance of unallotted securities under scheme(s) from previous return:            7,731,779
 Plus:  The amount by which the block scheme(s) has been increased since the       n/a
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period:        nil
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        7,731,779
 Number and class of securities originally admitted and the date of admission      USOS Total: 3,882,912

                                                                                   814,424 25 May 2011

                                                                                   1,202,280             8 October 2013

                                                                                   1,466,208             25 May 2017

                                                                                   400,000 30 May 2018

                                                                                   USIS Total: 425,000

                                                                                   425,000 30 November 2018

                                                                                   EMI Total: 7,012,088

                                                                                   1,520,576             25 May 2011

                                                                                   1,467,720             8 October 2013

                                                                                   1,893,792             25 May 2017

                                                                                   790,000                30 May 2018

                                                                                   1,340,000             30 November 2018

 

-ENDS-

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt

Email: futuramedical@optimumcomms.com (mailto:futuramedical@optimumcomms.com)

Tel: +44 (0) 203 882 9621

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Current therapeutic areas are sexual
health, including erectile dysfunction, and pain relief. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment
for erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has conducted a Phase 3 study using MED3000 in ED, referred to as
"FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment baseline,
consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3
(internationally accepted clinical trial endpoints in ED) with over 60% of
patients experiencing a clinically meaningful improvement in their ED.
MED3000 also begins to work immediately in some patients, with 60% of patients
seeing onset of their erection within 10 minutes of application. MED3000 is CE
marked in Europe and the UK as a clinically proven topical treatment
for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(https://www.futuramedical.com/)

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRUBASRUBUVUAR